120 related articles for article (PubMed ID: 26202943)
21. Structural insights of JAK2 inhibitors: pharmacophore modeling and ligand-based 3D-QSAR studies of pyrido-indole derivatives.
Gade DR; Kunala P; Raavi D; Reddy PK; Prasad RV
J Recept Signal Transduct Res; 2015 Apr; 35(2):189-201. PubMed ID: 25140764
[TBL] [Abstract][Full Text] [Related]
22. Biology and chemistry of the inhibition of nitric oxide synthases by pteridine-derivatives as therapeutic agents.
Matter H; Kotsonis P
Med Res Rev; 2004 Sep; 24(5):662-84. PubMed ID: 15224385
[TBL] [Abstract][Full Text] [Related]
23. Molecular modelling on small molecular CDK2 inhibitors: an integrated approach using a combination of molecular docking, 3D-QSAR and pharmacophore modelling.
Yuan H; Liu H; Tai W; Wang F; Zhang Y; Yao S; Ran T; Lu S; Ke Z; Xiong X; Xu J; Chen Y; Lu T
SAR QSAR Environ Res; 2013 Oct; 24(10):795-817. PubMed ID: 23941641
[TBL] [Abstract][Full Text] [Related]
24. Validation of TZD Scaffold as Potential ARIs: Pharmacophore Modeling, Atom-based 3D QSAR and Docking Studies.
Dahiya L; Mahapatra MK; Kaur R; Kumar V; Kumar M
Comb Chem High Throughput Screen; 2017; 20(4):310-320. PubMed ID: 28302016
[TBL] [Abstract][Full Text] [Related]
25. QSAR Studies of Nitric Oxide Synthase Inhibitors.
Tsopka IC; Hadjipavlou-Litina D
Curr Top Med Chem; 2023; 23(29):2723-2734. PubMed ID: 38093588
[TBL] [Abstract][Full Text] [Related]
26. 3D-QSAR and receptor modeling of tyrosine kinase inhibitors with flexible atom receptor model (FLARM).
Peng T; Pei J; Zhou J
J Chem Inf Comput Sci; 2003; 43(1):298-303. PubMed ID: 12546565
[TBL] [Abstract][Full Text] [Related]
27. 3D-QSAR and docking studies of aminopyridine carboxamide inhibitors of c-Jun N-terminal kinase-1.
Yi P; Qiu M
Eur J Med Chem; 2008 Mar; 43(3):604-13. PubMed ID: 17602798
[TBL] [Abstract][Full Text] [Related]
28. Development of predictive 3D-QSAR CoMFA and CoMSIA models for beta-aminohydroxamic acid-derived tumor necrosis factor-alpha converting enzyme inhibitors.
Murumkar PR; Gupta SD; Zambre VP; Giridhar R; Yadav MR
Chem Biol Drug Des; 2009 Jan; 73(1):97-107. PubMed ID: 19152638
[TBL] [Abstract][Full Text] [Related]
29. Current trends in QSAR on NO donors and inhibitors of nitric oxide synthase (NOS)*.
Kontogiorgis CA; Hadjipavlou-Litina D
Med Res Rev; 2002 Jul; 22(4):385-418. PubMed ID: 12111751
[TBL] [Abstract][Full Text] [Related]
30. Structural characterization of plasmodial aminopeptidase: a combined molecular docking and QSAR-based in silico approaches.
Wang F; Hu X; Zhou B
Mol Divers; 2019 Nov; 23(4):965-984. PubMed ID: 30730017
[TBL] [Abstract][Full Text] [Related]
31. [Three dimensional quantitative structure activity relationship of P450(17) alpha inhibitors of 17-substituted steroids].
Miao J; Ling YZ; Zhu N; Lei XP
Yao Xue Xue Bao; 2001 Jul; 36(7):507-10. PubMed ID: 12585081
[TBL] [Abstract][Full Text] [Related]
32. A QSAR analysis of 2-phenoxy-N-substituted acetamide analogues as hypoxia-inducible factor-1(HIF-1) inhibitors: a rational approach to anticancer drug design.
Noolvi MN; Patel HM; Kamboj S
Med Chem; 2012 Jul; 8(4):599-614. PubMed ID: 22530909
[TBL] [Abstract][Full Text] [Related]
33. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW
J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500
[TBL] [Abstract][Full Text] [Related]
34. Ligand based validated comparative chemometric modeling and pharmacophore mapping of aurone derivatives as antimalarial agents.
Adhikari N; Halder AK; Mondal C; Jha T
Curr Comput Aided Drug Des; 2013 Sep; 9(3):417-32. PubMed ID: 24010937
[TBL] [Abstract][Full Text] [Related]
35. 3D QSAR pharmacophore, CoMFA and CoMSIA based design and docking studies on phenyl alkyl ketones as inhibitors of phosphodiesterase 4.
Gaurav A; Singh R
Med Chem; 2012 Sep; 8(5):894-912. PubMed ID: 22741782
[TBL] [Abstract][Full Text] [Related]
36. Pharmacophore modeling, 3D-QSAR and DFT studies of IWR small-molecule inhibitors of Wnt response.
Kirubakaran P; Karthikeyan M
J Recept Signal Transduct Res; 2013 Oct; 33(5):276-85. PubMed ID: 23914783
[TBL] [Abstract][Full Text] [Related]
37. Pharmacophore-based screening and drug repurposing exemplified on glycogen synthase kinase-3 inhibitors.
Crisan L; Avram S; Pacureanu L
Mol Divers; 2017 May; 21(2):385-405. PubMed ID: 28108896
[TBL] [Abstract][Full Text] [Related]
38. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors.
Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
Drug Metab Dispos; 2000 Aug; 28(8):994-1002. PubMed ID: 10901712
[TBL] [Abstract][Full Text] [Related]
39. Combined ligand and structure-based approaches on HIV-1 integrase strand transfer inhibitors.
Reddy KK; Singh SK
Chem Biol Interact; 2014 Jul; 218():71-81. PubMed ID: 24792351
[TBL] [Abstract][Full Text] [Related]
40. Spectroscopic and quantum/classical mechanics based computational studies to compare the ability of Andrographolide and its derivative to inhibit Nitric Oxide Synthase.
A S BG; Prasana JC; Muthu S; Abraham CS; David HA
Spectrochim Acta A Mol Biomol Spectrosc; 2019 Jul; 218():374-387. PubMed ID: 31030004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
